Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

370

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2032

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab deruxtecan

Experimental drug. Provided in 100mg vials. IV infusion.

DRUG

Docetaxel

Active comparator. IV infusion.

DRUG

Paclitaxel

Active comparator. IV infusion.

DRUG

Carboplatin

Active comparator. IV infusion.

DRUG

Trastuzumab

Active comparator. IV infusion.

DRUG

Pertuzumab

Active comparator. IV infusion.

DRUG

Ribociclib

Experimental drug. Tablets.

DRUG

Letrozole

Experimental drug. Tablets.

DRUG

Epirubicin

Active comparator. IV infusion.

DRUG

Cyclophosphamide

Active comparator. IV infusion.

Trial Locations (7)

11219

NOT_YET_RECRUITING

Sankt Gorans Hospital, Stockholm

11861

NOT_YET_RECRUITING

Stockholm Southern Hospital, Stockholm

17164

RECRUITING

Karolinska University Hospital, Stockholm

21428

NOT_YET_RECRUITING

Skåne University Hospital, Malmo

70185

NOT_YET_RECRUITING

Örebro University Hospital, Örebro

75185

NOT_YET_RECRUITING

Uppsala University Hospital, Uppsala

90185

NOT_YET_RECRUITING

Norrlands University Hospital, Umeå

All Listed Sponsors
lead

Karolinska University Hospital

OTHER